Navigation Links
NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza

DENVER, Feb. 13 /PRNewswire/ -- Rocky Mountain Biosystems, Inc.(R) (RMBI), a Denver area biomedical technology company, announced receipt of a grant award of approximately $600,000 over two years from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) to develop its Self-Administered Vaccination Electromechanical (SAVE) technology for influenza vaccination. In the event of a pandemic, this needle-free system could be rapidly disseminated to provide protection against a deadly influenza outbreak, such as H5N1 influenza or bird flu. RMBI's technology has the potential to improve vaccine effectiveness to protect against a range of agents, including potential bioterror agents, by delivering therapeutics directly through the skin without needles, thus reducing required dosage and extending vaccine supplies. The RMBI technology and research may also improve population protection against annual seasonal influenza.

The SAVE device design is a lightweight, wristwatch-size vaccination system that delivers the vaccine in minutes, at pennies per application. "With RMBI's SAVE technology, we believe we can deliver vaccine protection to nearly all of the U.S. population within days of an outbreak. In addition, the effectiveness of RMBI's technology may reduce the amount of vaccine required, as well as provide greater immunity to the very young and elderly," noted Kevin Marchitto, RMBI's CEO.

RMBI's direct delivery through the skin is designed to 1) provide a means for individuals to immunize themselves, 2) rapidly deploy to hundreds of millions, within days of an emerging threat, 3) improve the lifetime and stability of vaccines, and their ability to be stored for long duration, and 4) improve vaccine efficiency and effectiveness to minimize chronic vaccine supply problems.

The SAVE vaccine delivery technology is being developed at Rocky Mountain Biosystems, Inc., a 6-year-old biomedical company located in the Denver metro area. RMBI blends technologies with experience to improve medical outcomes through tissue sealing and transdermal drug delivery technology to improve delivery and absorption of vaccines and therapeutics.

This release was issued through WebWire(R). For more information visit

SOURCE Rocky Mountain Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... join physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for ... held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
(Date:11/30/2015)... , Nov. 30, 2015 Spherix ... company committed to the fostering and monetization of ... current and prospective initiatives designed to create shareholder ... Executive Officer of Spherix. "Based on published reports, ... licensees exceeds $50 billion and Spherix will seek ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):